AstraZeneca PLC (AZN)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $286.07B
Last updated: Nov 17, 2026 at 4:43 PM ET
AstraZeneca PLC (AZN) Statistics
AstraZeneca (AZN) has a market cap of $286.07B and an enterprise value of $309.56B. Its trailing P/E of 22.2x is below its 10-year median of 39.7x.
Total Valuation
Enterprise value is 8.21% above the market cap, as debt exceeds cash.
| Market Cap | $286.07B |
|---|---|
| Enterprise Value | $309.56B |
| Latest price (Nov 17, 2026) | $182.36 |
Key Dates
The last ex-dividend date was Aug 7, 2026.
| Last Earnings Date | Oct 30, 2026 |
|---|---|
| Last Ex-Dividend Date | Aug 7, 2026 |
| Last Payment Date | Sep 8, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 4.6x and 5.5x. Its year-end P/E ranged from 25.2x to 64.0x from 2016 to 2025.
| P/E Ratio | 22.2x |
|---|---|
| Forward P/E | 17.5x |
| P/S Ratio | 4.6x |
| Forward P/S | 4.5x |
| P/B Ratio | 5.5x |
| P/FCF Ratio | 30.5x |
| P/OCF Ratio | 21.5x |
| PEG Ratio | 1.8 |
Enterprise Valuation
Counting debt and cash, the company is valued at 14.4x EBITDA and 33.0x free cash flow.
| EV / Earnings | 28.2x |
|---|---|
| EV / Sales | 5.0x |
| EV / EBITDA | 14.4x |
| EV / EBIT | 20.7x |
| EV / FCF | 33.0x |
Price Statistics
The stock is up 4.48% over 52 weeks and trades 7.47% above its 50-day average.
| Beta (1Y) | 0.22 |
|---|---|
| 52-Week Change | +4.48% |
| 1-Month Change | +11.23% |
| 3-Month Change | +10.55% |
| 6-Month Change | -0.58% |
| 5-Year Change | +49.61% |
| 10-Year Change | +229.54% |
| Total Return (1Y) | +7.55% |
| Total Return (3Y CAGR) | +14.83% |
| Total Return (5Y CAGR) | +12.37% |
| Return vs SPY (1Y) | -7.61% |
| Max Drawdown (1Y) | -25.84% |
| Max Drawdown (3Y) | -27.87% |
| Sharpe Ratio (1Y) | 0.14 |
| Correlation with SPY (1Y) | 0.11 |
| 50-Day Average | $169.68 |
| 200-Day Average | $179.34 |
| 52-Week Range | $152.40 to $209.11 |
| RSI (14 Days) | 57.7 |
| Average Volume (20 Days) | 2.89M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.01x current liabilities, and total debt is 0.61x shareholder equity.
| Current Ratio | 1.01x |
|---|---|
| Quick Ratio | 0.79x |
| Debt / Equity | 0.61x |
| Debt / EBITDA | 1.47x |
| Debt / FCF | 3.37x |
| Interest Coverage | 8.45x |
Returns and Efficiency
Return on invested capital is 14.95% over the last 12 months, against a 5-year average of 8.55%.
| Return on Equity (ROE) | 21.28% |
|---|---|
| Return on Assets (ROA) | 9.18% |
| Return on Invested Capital (ROIC) | 14.95% |
| Return on Capital Employed (ROCE) | 16.91% |
| ROE (5Y Average) | 12.54% |
| ROA (5Y Average) | 5.03% |
| ROIC (5Y Average) | 8.55% |
| Asset Turnover | 0.53x |
| Inventory Turnover | 1.79x |
| Receivables Turnover | 3.85x |
| Cash Conversion Cycle | -386 days |
Taxes
Income tax took 17.02% of pretax income over the last 12 months.
| Income Tax (TTM) | $2.25B |
|---|---|
| Effective Tax Rate | 17.02% |
Scores
AZN has an Altman Z-Score of 3.61, in the safe zone above 2.99, and a Piotroski F-Score of 8 of 9, in the strong band of 8 or 9.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 3.61 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 8 of 9 |
| Piotroski Strength | Strong |
Income Statement
Revenue was $62.17B over the last 12 months.
| Revenue | $62.17B |
|---|---|
| Gross Profit | $49.79B |
| Operating Income | $14.71B |
| Pretax Income | $13.25B |
| Net Income | $10.99B |
| EBITDA | $21.37B |
| EBIT | $14.96B |
| Reported EPS (TTM) | $8.20 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 43.14% of the $119.71B in total assets.
| Cash and Equivalents | $7.92B |
|---|---|
| Total Debt | $31.41B |
| Net Debt | $23.49B |
| Working Capital | $180.68M |
| Shareholder Equity | $51.64B |
| Tangible Book Value | -$7.56B |
| Total Assets | $119.71B |
| Total Liabilities | $67.99B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $4.01B of capital spending, operating cash flow left $9.32B of free cash flow.
| Operating Cash Flow | $13.33B |
|---|---|
| Capital Expenditures | $4.01B |
| Free Cash Flow | $9.32B |
| FCF Per Share | $6.01 |
| Depreciation and Amortization | $6.41B |
| Dividends Paid | $4.95B |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 23.66%, against a 5-year average of 14.21%.
| Gross Margin | 80.09% |
|---|---|
| Operating Margin | 23.66% |
| Pretax Margin | 21.31% |
| Net Margin | 17.68% |
| EBITDA Margin | 34.38% |
| EBIT Margin | 24.07% |
| FCF Margin | 14.99% |
| Gross Margin (5Y Average) | 76.76% |
| Operating Margin (5Y Average) | 14.21% |
| Net Margin (5Y Average) | 10.24% |
Growth
Revenue grew 9.82% a year over 3 years, and EPS 12.20% a year.
| Revenue Growth (3Y CAGR) | +9.82% |
|---|---|
| Revenue Growth (5Y CAGR) | +17.15% |
| EPS Growth (3Y CAGR) | +12.20% |
| EPS Growth (5Y CAGR) | +17.80% |
| FCF Growth (3Y CAGR) | +6.21% |
| FCF Growth (5Y CAGR) | +31.64% |
| Operating Income Growth (3Y CAGR) | +54.08% |
Dividends and Yields
AZN pays out 12.51% of earnings as dividends.
| Dividend Per Share (Annual) | $2.14 |
|---|---|
| Dividend Yield | 1.17% |
| Dividend Growth (3Y CAGR) | +3.29% |
| Dividend Growth (5Y CAGR) | +2.40% |
| Payout Ratio | 12.51% |
| FCF Payout Ratio | 53.10% |
| Earnings Yield | 4.50% |
| FCF Yield | 3.28% |
| Shareholder Yield | 1.74% |
Stock Splits
The last split was a 1-for-2 reverse split on Feb 2, 2026.
| Last Split Date | Feb 2, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:2 |
Peer Position
Against 9 similar companies, AZN has the 5th highest P/E.
P/E RatioPeer median 19.8x
P/S RatioPeer median 5.3x
ROICPeer median 13.48%
Dividend YieldPeer median 2.69%
| P/E Ratio | 22.2x vs 19.8x median |
|---|---|
| P/S Ratio | 4.6x vs 5.3x median |
| ROIC | 14.95% vs 13.48% median |
| Dividend Yield | 1.17% vs 2.69% median |
Analyst Forecast
Consensus estimates put revenue growth at 7.15% and EPS growth at 29.04% a year over the next 5 fiscal years.
| Revenue Growth Forecast (5Y CAGR) | +7.15% |
|---|---|
| EPS Growth Forecast (5Y CAGR) | +29.04% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About AZN
What is AZN's market cap?
AstraZeneca has a market cap of $286.07B. Its enterprise value, which adds debt and subtracts cash, is $309.56B.
What is AZN's P/E ratio?
AstraZeneca has a trailing P/E ratio of 22.2x and a forward P/E of 17.5x.
How many shares of AZN are outstanding?
AstraZeneca has 1.56B shares outstanding. The count is down 0.06% from a year earlier.
Does AZN pay a dividend?
Yes. AstraZeneca pays $2.14 a share a year, a dividend yield of 1.17%.
How much debt does AZN have?
AstraZeneca has $31.41B of total debt and $7.92B of cash and equivalents, a net debt position of $23.49B.
AZN pages: Overview, Dividends, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts